Healthcare services provider Park Medi witnessed strong investor interest on Monday after the company announced the acquisition of V3 Healthcare Private Limited, the operator of The Medicity Hospital in Rudrapur, Uttarakhand, in a transaction valued at nearly Rs 177 crore.

The stock rose more than 8 percent during intraday trade and touched a fresh record high of Rs 281 per share on the NSE. The rally extended gains seen over the previous trading session, reflecting investor optimism around the company’s expansion strategy and long-term capacity addition plans.

According to the company’s exchange filing, the board approved the acquisition through an all-cash transaction at its meeting held on May 25. The acquisition involves V3 Healthcare Private Limited, which runs The Medicity Hospital in Rudrapur’s Udham Singh Nagar district. The hospital currently operates with a capacity of 330 beds and is among the NABH-accredited multi-super speciality hospitals in the Kumaon region.

The transaction appears strategically aligned with Park Medi’s broader effort to deepen its presence in tier-2 and underserved healthcare markets, where demand for organised tertiary healthcare infrastructure has been steadily rising. While India’s healthcare investments have historically remained concentrated in metro cities, hospital operators are increasingly targeting semi-urban and regional clusters due to lower competitive intensity and improving affordability.

The acquisition also provides Park Medi with an immediate operational base in Uttarakhand, reducing the time and capital typically required for greenfield hospital development. The company stated that the acquisition is expected to generate operational synergies and economies of scale, particularly as it seeks to increase the contribution of its super speciality segment.

Management commentary suggests the company is positioning itself for accelerated earnings growth over the next few financial years. The company has projected revenue contribution of Rs 100 crore from the acquired business in FY27, alongside EBITDA of Rs 20 crore and profit after tax of Rs 12 crore. For FY28, revenue guidance from the acquisition has been raised further to Rs 120 crore, with EBITDA expected at Rs 25 crore.

These projections indicate management confidence in improving occupancy, service mix, and operational efficiency at the acquired hospital. The emphasis on super speciality healthcare is also noteworthy. Management expects the segment’s contribution to increase to 70–75 percent from the current 65 percent, suggesting a deliberate shift toward higher-margin treatment categories.

The company’s expansion roadmap extends beyond the Uttarakhand acquisition. Management disclosed plans to add 1,500 beds over the coming years, including 500 beds across Delhi and Kanpur, while another 1,000 beds are planned in FY28. This scale-up reflects the growing consolidation trend within India’s hospital industry, where mid-sized operators are aggressively expanding to capture rising healthcare demand driven by urbanisation, lifestyle diseases, insurance penetration, and government healthcare initiatives.

From a market perspective, investors are likely viewing the acquisition positively because it combines immediate scale expansion with a relatively asset-backed healthcare business. The hospital sector has remained resilient despite broader market volatility, particularly as healthcare demand in India continues to outpace infrastructure availability in several regions.

However, execution remains a critical factor. Integrating hospital operations, improving occupancy utilisation, retaining medical talent, and managing cost structures are all essential for delivering the projected profitability targets. Healthcare acquisitions also typically involve regulatory, operational, and staffing complexities that can delay expected synergies.

Another important element for investors is the company’s funding strategy. Management stated that most future bed additions are expected to be financed through internal accruals, although debt may be raised if required for expansion. This may offer some comfort regarding balance sheet discipline, especially at a time when rising interest costs remain a concern for expansion-focused companies.

At the same time, the aggressive revenue targets outlined by management — Rs 2,080 crore for FY27 and Rs 2,550 crore for FY28 — indicate that the company is entering a high-investment growth phase. While successful execution could strengthen its position in the regional healthcare ecosystem, any slowdown in occupancy growth or delays in planned expansions may impact profitability timelines.

For the broader healthcare sector, the deal reinforces the ongoing shift toward organised hospital chains expanding beyond major metros into regional healthcare markets. This trend is likely to intensify as operators seek scalable growth opportunities in areas with limited access to advanced medical facilities.

The acquisition also highlights how hospital operators are increasingly pursuing inorganic expansion to accelerate market penetration instead of relying solely on time-intensive greenfield projects. If executed efficiently, such strategies can improve regional healthcare access while simultaneously enhancing operating leverage for hospital chains.